{
    "Trade/Device Name(s)": [
        "Liquichek Tumor Marker Control-level 1",
        "Liquichek Tumor Marker Control-level 2",
        "Liquichek Tumor Marker Control-level 3",
        "Liquichek Tumor Marker Control-Trilevel Minipak",
        "Liquichek Tumor Marker Control"
    ],
    "Submitter Information": "Bio-Rad Laboratories",
    "510(k) Number": "K163015",
    "Predicate Device Reference 510(k) Number(s)": [
        "K071675"
    ],
    "Regulatory Class": "Class I, Reserved",
    "Product Code(s)": [
        "JJY"
    ],
    "Summary Letter Date": "October 26, 2016",
    "Summary Letter Received Date": "October 28, 2016",
    "Submission Date": "January 3, 2017",
    "Regulation Number(s)": [
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Quality control material (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "cancer molecular",
        "chemistry"
    ],
    "Analyte(s)": [
        "Alpha Fetoprotein (AFP)",
        "Beta-2-Microglobulin (B2-M)",
        "CA 15-3",
        "CA 19-9",
        "CA 27.29",
        "CA 125",
        "Carcinoembryonic Antigen (CEA)",
        "Ferritin",
        "Human Chorionic Gonadotropin (hCG)",
        "\u03b2-hCG",
        "Total hCG",
        "Intact hCG",
        "Insulin-like Growth Factor-I (IGF-1)",
        "Prostatic Acid Phosphatase (PAP)",
        "Prolactin",
        "Prostate Specific Antigen, Total (Total PSA)",
        "Prostate Specific Antigen, Free (Free PSA)"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "Quality control material"
    ],
    "Document Summary": "FDA 510(k) summary for Bio-Rad Liquichek Tumor Marker Control, a multi-analyte assayed quality control serum for tumor marker analytes",
    "Indications for Use Summary": "Intended for use as an assayed quality control serum to monitor the precision of laboratory testing procedures for the listed analytes",
    "fda_folder": "Clinical Chemistry"
}